4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Meeting Abstract

    Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Meeting Abstract

    Harding, J.; Ikeda, M.; Goyal, L.; Rodon, J.; Bai, L.; Oh, D.; Park, J.; Chen, L.; Ueno, M.; Liao, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
    Meeting Abstract

    Oaknin, A.; Meric-Bernstam, F.; Lang, J.; Ciombor, K.; Ray-Coquard, I.; Oza, A.; Yonemori, K.; Xu, R.; Zhao, J.; Gajavelli, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
    Meeting Abstract

    Macarulla, T.; Harding, J.; Morizane, C.; Ohkawa, K.; Ueno, M.; Vogel, A.; Lamarca, A.; Yamamoto, N.; Javle, M.; Hu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Meeting Abstract

    Harding, J.; Perez, C.; Kato, S.; Sharma, M.; Garmezy, B.; Quah, C.; Tam, B.; Severson, P.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
    Meeting Abstract

    O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: A large, multicenter, cohort study
    Meeting Abstract

    Mazzoli, G.; Nichetti, F.; Shitara, K.; Cohen, R.; Lonardi, S.; Elez, E.; Fakih, M.; Klempner, S.; Jayachandran, P.; Maron, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Preoperative treatment of locally advanced rectal cancer
    Journal Article

    Schrag, D.; Qian, S.; Weiser, M. R.; Gollub, M. J.; Saltz, L. B.; Musher, B. L.; Goldberg, J.; Al Baghdadi, T.; Goodman, K. A.; McWilliams, R. R.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Risk of sexual dysfunction in men treated with pelvic radiation therapy for locally advanced rectal cancer: 20 years of experience with 451 patients
    Meeting Abstract

    Patel, K. H.; Tringale, K. R.; Kim, N.; Boe, L.; Reyngold, M.; Wu, A. J.; Zinovoy, M.; Romesser, P. B.; Cuaron, J.; Pappou, E.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer – Evaluating radiation, ablation and surgery (ERASur)
    Meeting Abstract

    Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save